Amphista Therapeutics announces presentation of new preclinical data from its SMARCA2 and TEAD Targeted GlueTM degrader programs at AACR 2026, and publication of the first data on its TEAD program

AI Briefing

• – Amphista Therapeutics presents new preclinical data on SMARCA2 and TEAD Targeted Glue programs at AACR 2026.
• – Company's TEAD program yields first data on optimization of early Targeted Glue degraders.
• – Amphista Therapeutics' Targeted Glue programs focus on non-cereblon/non-VHL cancer targets.